ODT - Odonate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Odonate Therapeutics, Inc.

4747 Executive Drive
Suite 510
San Diego, CA 92121
United States

Full Time Employees117

Key Executives

NameTitlePayExercisedYear Born
Mr. Kevin C. TangChairman & CEO1N/A1967
Mr. John G. LemkeyChief Operating Officer271.92kN/A1981
Dr. Joseph P. O'Connell M.D.Chief Medical Officer501.93kN/A1954
Mr. Michael S. HearneCFO & Principal Accounting OfficerN/AN/A1963
Dr. Steven S. Pfeiffer Ph.D.VP of Technical OperationsN/AN/A1976
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Corporate Governance

Odonate Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.